Thermo Fisher Scientific Inc
TMO
Jodie read · what matters now
The company pulled $44.6B in sales with a 15.0% net margin, yet trades at a 32.5x P/E that leaves the math hinging more on multiples than growth.
The story is only the start. Jodie keeps watching the filing evidence, the companies connected to TMO, and whether its market group begins moving.
Earlier comparable assessment · baseline
The latest filing presents a mixed picture
10-Q filed 2026-05-01 against the comparable filing from 2025-05-02.
A newer Struct brief is shown above. This older assessment remains here for comparison, not as the current read.
What improved
- Revenue increased 6.2% versus the comparable filing period.
What weakened
No thresholded deterioration was identified.
Filing receipts
“Three months ended (Dollars in millions) March 28, 2026 March 29, 2025 Revenues Life Sciences Solutions $ 2,636 $ 2,341 Analytical Instruments 1,716 1,718 Specialty Diagnostics 1,142 1,148 Laboratory Products and Biopharma Services 6,036 5,640 Eliminations (524) (482) Consolidated revenues $ 11,005 $ 10,364 Life Sciences Solutions Three months ended Organic (non-GAAP measure) (Dollars in millions) March 28, 2026 March 29, 2025 Total Change Acquisitions/ Divestitures Currency Translation Revenues $ 2,636 $ 2,341 13 % 9 % 3 % 1 % Segment income 954 834 14 % Segment income margin 36.2 % 35.6 % 0.6 pt The increase in organic revenues in the first quarter of 2026 was primarily driven by the biop...”
“Laboratory Products and Biopharma Services Three months ended Organic (non-GAAP measure) (Dollars in millions) March 28, 2026 March 29, 2025 Total Change Acquisitions/ Divestitures Currency Translation Revenues $ 6,036 $ 5,640 7 % 1 % 2 % 4 % Segment income 778 731 6 % Segment income margin 12.9 % 13.0 % (0.1) pt The increase in organic revenues in the first quarter of 2026 was primarily due to strong growth in the clinical research business and the research and safety market channel.”
“Changes in other assets and liabilities used cash of $0.45 billion primarily due to the timing of payments for compensation and income taxes.”
Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.
Who this business touches
The relationships behind TMO
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
Filing peers
Companies whose filings use similar operating language.
You can see the shape of the network here. Pro opens 31 more links, the original filing receipts, and alerts when connected names begin moving. See Pro →
What is moving around it
Live connections
TMO is currently a Participant in the organic co-movement group Healthcare Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Theme membership history
No durable theme membership has been observed for this name yet.